

CURRICULUM VITAE

Fady Geara MD, PhD

Professor and Chairman, Department of Radiation Oncology

Founding Director, The Naef K. Basile Cancer Institute

The American University of Beirut Medical center

Email: fg00@au.edu.lb

Phone: +961 1 344839

Summary of degrees and appointments

- 1985 **MD degree**, University of Paris XI, School of medicine, France
1990 Radiation Oncology diploma, University of Tours, France
1989-1991 Visiting Scientist; The University of Texas, MD Anderson Cancer Center
1992 **PhD degree** in Radiation Biology, University of Paris XI and MD Anderson Cancer Center
1991-1993 Clinical Fellow; The University of Texas, MD Anderson Cancer Center
1993 Faculty Associate, Dept of Radiation Oncology, MD Anderson Cancer Center
1994 **American Board of Radiology in Radiation Oncology**
1993-97 Assistant Professor, Dept of Radiation Oncology, MD Anderson Cancer Center
1997-03 Associate Professor and Chairman, Dept of Radiation Oncology, The American University of Beirut Medical center
2007-12 **Founding Director**, The Naef K. Basile Cancer Institute
 The American University of Beirut Medical center
2003- **Professor and Chairman**, Dept of Radiation Oncology, The American University of Beirut Medical center

Summary of research and teaching

- Number of published papers: 98
Number of published abstracts: 65
Number of invited lectures: 223

A. Personal Experience

Personal Information

Fady Geara MD, PhD

Professor and Chairman
Department of Radiation Oncology,
American University of Beirut,
Riad El Solh 110 72020
Beirut, Lebanon.
Email: fg00@aub.edu.lb
Website: <http://staff.aub.edu.lb/~weboncol/>

Phone: 961 1 344839
Fax: 961 1 370795

Birth date: January 10, 1962, Lebanon
Country of Citizenship: USA
Marital Status: Married (Nathalie Kantarjian)
Licensure: USA, State of Texas, # J6833; Lebanese order of Physicians, # G265

Education and Degrees:

1994 American Board of Radiology, Radiation Oncology section
1993 Ph.D. in Radiation Biology, University of Paris XI, France; Research work done at MDACC.
1990 Radiation Oncology Diploma, University of Tours, France.
1990 Foreign Medical Graduate Examination in the Medical Sciences (FMGEMS)
1989 Dissertation of Medicine, M.D. Degree, University of Tours, France.
1989 Masters of Science degree in Radiobiology, University of Paris XI, France.
1985 Medical Graduation, University of Paris XI, France
1985 Medical Specialities Qualifying Examination, ("Concours d'Internat"), France
1979-85: Medical School, University of Paris XI, France

Professional experience

2003- : **Professor and Chairman**, Department of Radiation Oncology,
American University of Beirut, Beirut Lebanon
2007-12: **Director**, The Naef K. Basile Cancer Institute at The American University of Beirut Medical
Center
2004-07: **Director ad interim**, The Naef K. Basile Cancer Institute at The American University of
Beirut Medical Center
1997- 2003: **Associate Professor and Chairman**, Department of Radiation Oncology,
American University of Beirut, Beirut Lebanon
1994-97: **Assistant Professor**, Department of Radiation Oncology,
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas
1993-94: **Faculty Associate**, Department of Radiation Oncology,
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas
1991-93: **Clinical Fellow**, Radiation Oncology,
The University of Texas, M.D. Anderson Cancer Center, Houston TX
1989-91: **Visiting Scientist**, Experimental Radiation Oncology,
The University of Texas, M.D. Anderson Cancer Center, Houston TX
1985-89: **Resident** in Radiation Oncology, at the Institut Gustave Roussy (Villejuif), University
Hospital Henri Mondor (Creteil), and University Hospital Bretonneau (Tours), France.

Honors and Awards

- 2004: Elected to the Alpha Omega Alpha Honor Medical Society
1999- 01 Founding President, The Lebanese Society of Radiation Oncology
1995-97 The American Cancer Society Career Development Award in Clinical Oncology
1991-92 "The University Cancer Foundation Clinical Fellow for the year 1991-1992."
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas.

Grant Support

- 2010-14 Fogarty International Center, National Institutes of Health K01TW008409-01
Mentor and co-investigator: "Radiotherapy outcomes for children in developing versus developed countries."
Total amount: \$498,864
1998-03: International Atomic Energy Agency CRP E.3.30.18. American University of Beirut
"A randomized multicenter study of 5 versus 6 weekly fractions of radiotherapy in the treatment of squamous cell carcinoma of the head and neck"
Annual direct cost \$ 5000
1997-01: National Institutes of Health 2P01 CA-06294. M. D. Anderson Cancer Center, Houston, TX. Co-Project Director: "Predicting Normal Tissue Responses to Radiotherapy".
Annual direct costs \$128,511
1995-97: American Cancer Society Career development grant. Predicting normal tissue response to radiotherapy. Annual direct cost \$30,000
1991-96: National Institutes of Health 2P01 CA-06294. M. D. Anderson Cancer Center, Houston, TX. Co-Investigator Project VA: "In vitro sensitivity of lymphocytes, fibroblasts, and keratinocytes as predictors of normal tissue treatment reactions".
Annual direct costs \$85,076.
1989-90: Association for Cancer Research, France, M. D. Anderson Cancer Center, Houston, TX
Intratumor Heterogeneity of Squamous Cell Carcinomas.
Total amount: FF 148,824 (\$25,000)
1988-89: Association for Cancer Research, France (ARC), Institut G. Roussy, Villejuif, France
Estimation of Clonogenic Cell Fraction in Human Tumor Primary Cultures.
Total amount: FF 96,000 (\$16,270)

B. Research

Published Papers

1. **Geara FB**, Eid T, Zouain N, Thebian R, Andraos Th, Chehab Ch, Ramia P, Youssef B, Zeidan Y. Randomized, Prospective, Open-Label Phase III Trial Comparing Mebo® Ointment With Biafine® Cream For The Management of Acute Dermatitis During Radiotherapy For Breast Cancer. *Am J Clin Onc* 2018 (in press)
2. Refaat MM, Ballout JA, Zakka P, Hotait M, Al Feghali KA, Gheida IA, Saade C, Hourani M, **Geara F**, Tabbal M, Sfeir P, Jalbout W, Al-Jaroudi W, Jurjus A, Youssef B. Swine Atrioventricular Node Ablation Using Stereotactic Radiosurgery: Methods and In Vivo Feasibility Investigation for Catheter-Free Ablation of Cardiac Arrhythmias. *J Am Heart Assoc*. 2017 Oct 27;6(11). 10.1161/JAHA.117.007193.
3. **Geara FB**, Bulbul M, Khauli RB, Andraos TY, Abboud M, Al Mousa A, Sarhan N, Salem A, Ghatasheh H, Alnsour A, Ayoub Z, Gheida IA, Charafeddine M, Shahait M, Shamseddine A, Gheida RA, Khader J. Nadir PSA is a strong predictor of treatment outcome in intermediate and

- high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. *Radiat Oncol.* 2017 Sep 7;12(1):149: 10.1186/s13014-017-0884.
4. El Chediak A, Shamseddine A, Bodgi L, Obeid JP, **Geara FB**, Zeidan YH. Optimizing tumor immune response through combination of radiation and immunotherapy. *Med Oncol.* 2017 Aug 21;34(9):165: 10.1007/s12032-017-1025
 5. Hilal L, Al Feghali KA, Ramia P, Abu Gheida I, Obeid JP, Jalbout W, Youssef B, **Geara FB**, Zeidan YH. Intraoperative Radiation Therapy: A Promising Treatment Modality in Head and Neck Cancer. *Front Oncol.* 2017 Jul 7;7:148: 10.3389/fonc.2017.00148.
 6. Belkacemi Y, Truong PT, Khan AJ, **Geara FB**, Taghian AG, Moran MS. Adjuvant nodal radiotherapy in the era of sentinel node biopsy staging of breast cancer: A review of published guidelines and prospective trials and their implications on clinical practice. *Crit Rev Oncol Hematol.* 2017 Apr;112:171-178.
 7. Rondeau V, Pignon JP, Michiels S; MACH-NC collaborative Group. A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. *Stat Methods Med Res.* 2015 Dec;24(6):711-29.
 8. Zeidan YH, **Geara FB**. Lebanon: an evolving hub for radiation therapy in the arab world. *Int J Radiat Oncol Biol Phys.* 2015 Apr 1;91(5):888-91.
 9. Taddei PJ, Khater N, Zhang R, **Geara FB**, Mahajan A, Jalbout W, Pérez-Andújar A, Youssef B, Newhauser WD. Inter-Institutional Comparison of Personalized Risk Assessments for Second Malignant Neoplasms for a 13-Year-Old Girl Receiving Proton versus Photon Craniospinal Irradiation. *Cancers* 2015 Mar 10;7(1):407-26
 10. Foray N, Badie C, Alsbeih G, Lambin P, **Geara F**, Taghian AG, Deschavanne P, Gueulette J, Courdi A, Chavaudra N, Fertil B. Edmond-philippe malaise (1930-2013): a lifetime of perseverance leads to the cellular definition of intrinsic radiosensitivity. *Int J Radiat Oncol Biol Phys.* 2014 Apr 1;88(5):1215-7.
 11. Lataifeh I, Jaradat I, Seoud M, Youssef B, Barahmeh S, **Geara F**. Survival outcome after radiation therapy for patients with early cervical carcinoma undergoing inadequate primary surgery. *Int J Gynecol Cancer.* 2014 Jan;24(1):124-9.
 12. Dbouk H, Ajouz H, Shamseddine A, Mukherji D, O'Reilly EM, Haydar A, Kelsen D, Naghy M, Eloubeidi M, **Geara F**, Saltz L, Abou-Alfa GK. Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. *Gastrointest Cancer Res.* 2013 Jul;6(4):115-7.
 13. Taddei PJ, Jalbout W, Howell RM, Khater N, **Geara F**, Homann K, Newhauser WD. Analytical model for out-of-field dose in photon craniospinal irradiation. *Phys Med Biol.* 2013 Nov 7;58(21):7463-79.
 14. Hajj C, Goodman K, Kelsen D, Shia J, Shamseddine A, Naghy M, Sidani M, Eloubeidi M, Merhi F, **Geara F**, Ang C, Saltz L, Abou-Alfa GK. A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. *Gastrointest Cancer Res.* 2013 May;6(3):87-9.
 15. Alameddine R, Wehbe D, Weiser M, Segal N, Goodman K, Shamseddine A, Ang C, Haydar A, Sidani M, **Geara F**, Naghy M, O'Reilly EM, Abou-Alfa GK. Management of a locally advanced rectal cancer in a patient who declined surgery. *Gastrointest Cancer res.* 2012, Nov. 5 (6):205-9
 16. Belkacémi Y, Boussen H, Turkan S, Tsoutsou PG, **Geara F**, Gligorov J. Fight against cancer around the Mediterranean area: "Many hands make light work!" *Crit Rev Oncol Hematol.* 2012 S1040-8428(12)
 17. Tamraz S, Shamseddine A, Shah M, El-Oubeidi M, Zaatari G, **Geara F**, Lowery MA, O'Reilly EM, Al-Kutoubi A, Faraj W, Kelsen DP, Abou-Alfa GK. A 72-year-old man with duodenal adenocarcinoma. *Gastrointest Cancer Res.* 2012 May;5(3):93-6.
 18. Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O'Reilly EM, **Geara F**, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK. A case of advanced gastric cancer. *Gastrointest Cancer Res.* 2012 Mar;5(2):59-6.
 19. Kharfan-Dabaja MA, Otrrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. *Bone Marrow Transplant.* 2012 Jan 16.

20. Abboud M, Arabi A, Salti I, **Geara F**. Outcome of thyroid associated ophthalmopathy treated by radiation therapy. *Radiat Oncol*. 2011 May 13;6:46.
21. Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Siddiqui N, Al Saleh M, **Geara F**, Birido N, Al-Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A, Khatib S, El-Mistiri M, Salem D, Sayd el SH, Jaloudi M, Jahanzeb M, Gradishar WI; MENA Breast Cancer Regional Guidelines Committee. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. *J Natl Compr Canc Netw*. 2010 Jul;8 Suppl 3:S8-S15.
22. Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, **Geara FB**, Javaid M, Khader J, Khodadad K, Omar W, Saadeddin A, Sabe HA, Shadmeh MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D; MENA Lung Cancer Regional Guidelines Committee. Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. *J Natl Compr Canc Netw*. 2010 Jul;8 Suppl 3:S16-21.
23. El Saghir NS, El-Asmar N, Hajj C, Eid T, Khatib S, Bounedjar A, Ajarim D, Shamseddine A, **Geara F**, Jazieh A, Azim HA, Abdelkader Y, Kattan J, Abulkhair O. Survey of utilization of multidisciplinary management tumor boards in Arab countries. *Breast*. 2011; Suppl 2:S70-4.
24. El-Khatib M, **Geara F**, Haddadin MJ, Gali-Muhtasib H..Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21. *Radiat Oncol*. 2010;5:107.
25. Abboud M, Saghir NS, Salame J, **Geara FB**. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine. *Breast J*. 2010;16(6):644-6.
26. **Fady B Geara**, Ali Shamseddine, Ali Khalil, Mirna Abboud, Maya Charafeddine and Muhieddine Seoud. A phase II randomized trial comparing radiotherapy with concurrent cisplatin or weekly paclitaxel in patients with advanced cervical cancer. *Radiation Oncology* 2010, 5:84
27. Taddei PJ, Zhang R, Perez-Andujar A, Howell RM, Scarboro SB, Mahajan A, **Geara F**, Khater N, Giebeler A, Mirkovic D, Newhauser WD. Predicted risk of a radiation-induced second malignant neoplasm for a 9-year-old girl with medulloblastoma after proton versus photon craniospinal irradiation, 56th Annual Meeting of the Radiation Research Society, Wailea, Maui, HI, USA. Book of Abstracts, 184-185 (2010)
28. Hatoum HA, Jamali FR, El-Saghir NS, Musallam KM, Seoud M, Dimassi H, Abbas J, Khalife M, Boulos FI, Tawil AN, **Geara FB**, Salem Z, Shamseddine AA, Al-Feghali K, Shamseddine AI. Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer. *Ann Surg Oncol*. 2009
29. Haykal J, **Geara F**, Haddadin MJ, Smith CA, Gali-Muhtasib H. The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells. *Radiat Oncol*. 2009 Jul 14;4:25.
30. Abboud M, Haddad G, Kattar M, Aburiziq I, **Geara FB**. Extraneural metastases from cranial meningioma: a case report. *Radiat Oncol*. 2009 Jul 6;4:20.
31. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol*. 2009 Jul;92(1):4-14.
32. Hamdan AL, **Geara F**, Rameh C, Hussein ST, Eid T, Fuleihan N. Vocal changes following radiotherapy to the head and neck for non-laryngeal tumors. *Eur Arch Otorhinolaryngol*. 2009 Sep;266(9):1435-9.
33. Farhat FS, **Geara F**, Natout M, Serhal J, Daya W. Tongue carcinoma in an adult Down's syndrome patient: a case report. *World J Surg Oncol*. 2009 Mar 4;7:26.
34. Joelle M Haykal, MS; Pamela E Fernainy, MS; Wafica S Itani, MS; Makhluif J Haddadin, PhD; **Fady B Geara, MD**; Colin A Smith, PhD; Hala Gali-Muhtasib. Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide. *Radiotherapy Oncology* 2008 Mar;86(3):412-8.

35. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, **Geara F**, Seoud M, Shamseddine AI. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. *Int J Surg.* 2007 Aug;5(4):225-33.
36. **Fady B. Geara**, E. Nasr, SL. Tucker, M. Charafeddine, B. Dabaja, T. Eid, J. Abbas, Z. Salem, A. Shamseddine, P. Issa, N. Saghir. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: Influence of clinical presentation on outcome. *Int J Radiat Oncol Biol Phys.* 2007 Jun 1;68(2):364-9.
37. Azar C, Soweid A, Berro Z, Salem ZM, **Geara FB**, Kattar MM, Hashash JG, Barada KA. Duodenal mucosa-associated lymphoid tissue lymphoma successfully treated by radiation therapy. *Clin Lymphoma Myeloma.* 2007 May;7(6):428-31.
38. L. El-Zahabi, F. Jamali, I. El-Hajj, M. Naja, Z. Salem, A. Shamseddine, N. Saghir, G. Zaatari, **F. Geara**, A. Soweid. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to helicobacter pylori eradication. *Gastrointestinal Endoscopy* 0016-5107 doi: 10.1016/j.gie.2006.05.009
39. W. Itani, **F. Geara**, J. Haykal, M. Haddadin, H. Gali-Muhtasib. Radiosensitization by 2-benzoyl -3-phenyl-6, 7-dichloroquinoxaline 1, 4-dioxide under oxia and hypoxia in human colon cancer cells. *Radiation Oncology* 2007, 2:1 doi: 10.1186/1748-717X-2-1
40. W. Itani, **F. Geara**, J. Haykal, M. Haddadin, H. Gali-Muhtasib. Radiosensitization by DCQ under oxia and hypoxia in human colon cancer cells. *Radiation Oncology Journal, MS: 7869650821155456*
41. **Fady B. Geara**. Elie Nasr, Susan L. Tucker, Maya Charafeddine, Bouthaina Dabaja, Toufic Eid, Jaber Abbas, Ziad Salem, Ali Shamseddine, Philip Issa, Nagi El Saghir. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: Influence of clinical presentation on outcome. *Int J of Rad Oncol, Biol, phys* 2007;68(2):364-9
42. **Fady B. Geara**. A Critical Review of the Role of Radiation Therapy for Non small Cell and Small Cell Lung Cancers. Proceedings of the 16th Annual NEMROCK conference, Cairo; 2006; 132-8 **(Invited Review)**
43. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, **Geara FB**, Shamseddine AI. Effects of young age at presentation on survival in breast cancer. *BMC Cancer.* 2006 Jul 20;6:194.
44. El-Zahabi L MN, Jamali FR, El-Hajj II, Naja MO, Salem Z, Shamseddine A, El Saghir NS, Zaatari G, **Geara FB**, Soweid AM. The value of EUS in predicting the response of gastric malt lymphoma to helicobacter pylori eradication. *Gastrointestinal Endoscopy Journal.* 2006
45. El Saghir NS, Elhajj II, **Geara FB**, Hourani MH. Trauma-associated growth of suspected dormant micrometastasis. *BMC Cancer.* 2005 Aug 4;5:94.
46. El Saghir NS, Shamseddine A, **Geara F**, Bikhaz K, Rahal B, Salem Z, Taher A, Tawil A, Khatib Z, Abbas J, Hourani M, Khalil A, Seoud M. Breast cancer in Lebanon. Increased age-adjusted incidence rates in younger-aged groups at presentation: implications for screening and for Arab-American ethnic groups. *Ethn Dis.* 2005;15(1 Suppl 1):S1-11-2.
47. A. Shamseddine, M. Khalifeh, A. Chehal, A. Taher, R. Jalloul, N. Bitar, A. Dandashi, Y. Abou Mourad, J. Abbas, **F. Geara**. A Clinical Phase II study of Cisplatinum and Vinorelbine in Advanced Breast Carcinoma. *Am J Clin Onc* 2005;28(4):393-8
48. Seoud M, Khalil A, **Geara F**, Kaspar H, Abbas J. Long term survival following aggressive surgery and radiotherapy for pelvic fibromatosis. *Int J Gynecol Cancer* 2005,15, 1-3
49. El Saghir NS, Shamseddine A, **Geara F**, Bikhazi K, Rahal B, Salem Z, Taher A, Tawil A, Khatib Z, Abbas J, Hourani M, Khalil A, Seoud M. Breast cancer in Lebanon. Increased age-adjusted incidence rates in younger-aged groups at presentation: implications for screening and for Arab-American ethnic groups. *Ethn Dis.* 2005 Winter;15(1 Suppl 1):S1-11-S1-12.
50. **Fady B. Geara**, E. Nasr, SL. Tucker, E. Brihi, G. Zaytoun, Z. Salem, N. El Saghir, A. Shamseddine, P. Issa. Nasopharyngeal carcinoma in the Middle East: Experience of the American University of Beirut Medical Center. *Int J Rad Onc. Biol Phys* 2005 Apr 1;61(5):1408-15.
51. Prithvirajsinh S, Story MD, Bergh SA, **Geara FB**, Ang KK, Ismail SM, Stevens CM, Buchholz TA, Brock WA. Accumulation of the Common Mitochondrial Deletion Induced by Ionizing Radiation. *FEBS Lett.* 2004;571(1-3):227-32
52. HG Muhtasib, M. Sidani, **F. Geara**, J.Al-Hmaira, M. Assaf-Diab, M. J. Haddadin, G. Zaatari. Quinoxaline 1,4-dioxides are Novel Angiogenesis Inhibitors that Potentiate Antitumor Effects of Ionizing Radiation. *Int J Oncol.* 2004;24(5):1121-31.

53. M. Seoud, **F.B. Geara**, A. Shamseddine, Z. Salem, A. Khalil. Short Duration Neoadjuvant Chemotherapy Followed by Radiotherapy for Advanced Carcinoma of The Cervix: Results and Prognostic Variables. *Eur J Gynaecol Oncol.* 2003;24(2):163-8
54. Alsbeih G. Story MD, Maor MM, **Geara FB**, Brock WA. Chromosomal fragility and family history of radiosensitivity as indicators for radiotherapy dose modifications. *Radiother Oncol.* 2003;66(3):341-4.
55. N. El Saghir, A. Shamseddine, **F. B. Geara**, A. Tawil, A. Taher, Z. Salem, A. Khalil, and M. Seoud. Age Distribution of Breast Cancer in Lebanon: Analysis of 2282 cases from the American University of Beirut Medical Center. *The Lebanese Medical Journal*, 2002; 50 (1-2); 3-9
56. Buchholz, Th, Xifeng Wu, Abu Hussain, SL.Tucker, G. B. Mills, B. Haffty, S Bergh, M. Story, **F. B. Geara**, W A. Brock. Evidence of Haplotype Insufficiency in Human Cells Containing a Germline Mutation in BRCA1 or BRCA2. *Int J Cancer.* 2002; 97:557-61.
57. **F.B. Geara**. Postoperative thoracic radiotherapy for lung cancer: Where is the benefit? The Cancer letter 2002; (2); 7. (Invited editorial)
58. Ang KK, Trotti A, Garden AS, Foote RL, Morrison WH, **Geara FB**, Klotch W, Peters LJ, Goepfert H. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2001; 51:571-8
59. Meyers C., **Geara F. B.**, Wong P.F, Morrison W.H. Neurocognitive effects of therapeutic irradiation for base of skull tumors. *Int J Radiat Oncol Biol Phys.* 2000; 46:51-5.
60. Muwakkit S, **Geara F**, Nabbout B, Farah R, Shabb N.S, Hajjar T, Khogali M. Treatment of pediatric hodgkin's disease with chemotherapy alone or combined modality therapy. *Radiat Oncol Invest* 1999; 7 (6): 365-373
61. **Fady Geara**. Radiotherapy for gastrointestinal lymphomas: indications and techniques. *Cancer Radiother* 1999; 3(2): 141-8
62. Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, **Geara F**, Clayman GL, Shin DM, Callender DL, Khuri FR, Goepfert H, Hong WK, Peters LJ. Phase I/II Trial of Radiation With Chemotherapy "Boost" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses. *J Clin Oncol* 1999, 17(8): 2390
63. Lieboss RH, Pollack A, Lankford SP, Zagars GK, von Eschenbach AC, **Geara FB**. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: An evaluation based on disease outcome. *Cancer* 1999; 85(7): 1577-85
64. Colletier P., Garden A., Morrison W., Goepfert H., **Geara F.**, Ang K. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymphnodes from unknown primary site: Outcomes and pattern of failure. *Head Neck* 20:674-681, 1998
65. Jiang GL, Morrison WH, Garden AS, **Geara F**, Callender D, Goepfert H, Ang KK. Ethmoid sinus carcinomas: natural history and treatment results. *Radiother Oncol* 1998 49:21-7
66. **Fady B. Geara**, Ritsuko Komaki, Susan L. Tucker, Isaac Rosen, Elizabeth L. Travis, James D. Cox. Factors Influencing the Development of Lung Fibrosis after Chemoradiation for Small Cell Carcinoma of the Lung: Evidence for Inherent Interindividual Variation. *Int. J. Radiat. Oncol. Biol. Phys.*; 41: 279-286. 1998
67. W.A. Brock, E. Abozina; S.P. Lankford; **F.B. Geara**. Human Diploid Fibroblasts undergo Terminal Differentiation/Senescence with minimal cell loss in response to low doses of ionizing radiation. In: Progress in Radio-oncology; 6th International Meeting; Monduzzi S.P.A. Ed.; Bologna, Italy; 35-41; 1998 (invited book chapter)
68. **F.B. Geara**. Modern Radiation Oncology: The Gold Standard. *The Cancer Letter* 1998, 5: 6 (invited Editorial)
69. **Fady B. Geara**. Stereotactic Radiation Delivery: A Major Advance in Radiation Oncology *The Medical Periodical* 1998; 1 (8); 15-16 (Local Journal-Invited article)
70. G. Sanguineti, **F. B. Geara**, A. S. Garden, S. L. Tucker, K.K. Ang, W. H. Morrison, L. J. Peters. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. *Int. J. Radiat. Oncol. Biol. Phys.* 37: 985-996: 1997
71. **Fady B. Geara**, G. Sanguineti, S. L. Tucker, A. S. Garden, K.K. Ang, W. H. Morrison, L. J. Peters. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. *Radiother. Oncol.*43: 53-61:1997

72. **Fady B. Geara**, B. S. Glisson; G. Sanguineti, S. L. Tucker, A. S. Garden, K. Kian Ang, G. L. Clayman, H. Goepfert, L. J. Peters, W. K. Hong. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in advanced nasopharyngeal carcinoma: Results of a matched cohort study. *Cancer* 79: 1279-1286; 1997
73. **F.B. Geara**, S. L. Tucker, W.A. Brock Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. In response to Burnet et al. *Int. J. Radiat. Oncol. Biol. Phys.* 38: 1137-1138; 1997 (letter to the editor)
74. S. L. Tucker, **F.B. Geara**, L.J. Peters, W.A. Brock. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? *Radiother. Oncol.* 1996, 38:103-113
75. **Fady B. Geara**, L. J. Peters, K. K. Ang, A.S. Garden, S. L. Tucker, L. Levy, B. W. Brown. Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 1996, 35:455-462.
76. A.S. Garden, W.H. Morrison, K. K. Ang, **F. B. Geara**, L. J. Peters. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? *Int. J. Radiat. Oncol. Biol. Phys.* 36: 1005-1012: 1996
77. W.A. Brock, **F. Geara**. The clinical relevance of normal tissue radiosensitivity. In: Hagen U, Harder D, Jung H, Streffer C, (eds). Xth International Congress of Radiation Research. Wurzburg, Germany: 1996: II: Congress Lectures: 843-846 (invited book chapter)
78. **Fady B. Geara**, Helmut Goepfert. Does neck stage predict local control after irradiation in treatment of head and neck cancer? A commentary. *Oncology*, 1996, 10:392-395 (Invited editorial)
79. **Fady B. Geara**, K. Kian Ang. Radiation treatment of malignant melanoma; in *Surgery Clinics of North America*, 76:1383-1398; 1996 (invited book chapter)
80. W.A. Brock, S. L. Tucker, **F.B. Geara**, I. Turesson, J. Wike, J. Nyman, L.J. Peters. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 1995, 32:1371-79
81. G. K. Zagars, **F. B. Geara**, A. Pollack. A. Von Eschenbach. The T-classification of clinically localized prostate cancer. An appraisal based on early disease outcome following radiation therapy. *Cancer*, 1994; 73:1904-12
82. **Fady B. Geara**, G. K. Zagars, Alan Pollack. Influence of the presenting symptoms on treatment outcome for prostate cancer treated by radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 1994, 30:331-37
83. **Fady B. Geara**, L. J. Peters, K. K. Ang, J.L. Wike, W.A. Brock. Prospective comparison between *in vitro* normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. *Int. J. Radiat. Oncol. Biol. Phys.* 1993, 27:1173-1179
84. W.A. Brock, **F. Geara**., L. J. Peters. Cellular radiosensitivity as a predictor of radiotherapy response. Head and Neck Cancer, Vol III; 851-856. J.T. Johnson and Didolkar, editors; Elsevier Science Publishers, 1993 (invited book chapter)
85. T. Girinsky, R. Lubin, N. Chavaudra, J.P. Pignon, J. Gazeau, C. Haie, P. Wilbault, G. Socie, J.M. Cosset, **F. Geara**, B. Fertil, W.A. Brock, E.P. Malaise. *In vitro* radiosensitivity and calculated cell growth fraction in primary cultures from head and neck and cervical carcinomas. Preliminary correlations with treatment outcome. *Rad. Res.* 1992, (2); 700-705.
86. **Fady B. Geara**, Lester J. Peters, K. Kian Ang, Jennifer L. Wike, William A. Brock. Radiosensitivity measurement of keratinocytes and fibroblasts from radiotherapy patients. *Int. J. Radiat. Oncol. Biol. Phys.*, 1992, 24: 287-293.
87. **Fady B. Geara**, Lester J. Peters, K. Kian Ang, Jennifer L. Wike, Susan Sivon, Roland Guttenburger, David Callender, Edmond P. Malaise, William A. Brock. Intrinsic radiosensitivity of human fibroblasts and lymphocytes after high- and low-dose rate irradiations. *Cancer Res.*, 1992, 52: 6348-6352.
88. W.A. Brock, **F. Geara**. Variations in human tumor and normal cell radiosensitivity: Possible implications for radiotherapy. *Cancer Bull.*, 1992, 44:117-123. (invited article)
89. **Fady Geara**, T. Girinski, N. Chavaudra, J.M. Cosset, B. Dubray, W.A. Brock, E.P. Malaise Estimation of clonogenic cell fraction in primary culture derived from squamous cell carcinomas. *Int. J. Radiat. Oncol. Biol. Phys.*, 1991, 21; 661-665

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

90. **Fady Geara**, J. P. Le Bourgeois, P. Piedbois, J.M. Pavlovich, J.J.Mazeron. Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma. *Int. J. Radiat. Oncol. Biol. Phys.*, 1991, 21; 1517-1522
91. **Fady Geara**, G. Calais, B. Chauvet, A. Reynaud-Bougnoux, O. Le Floch. Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases *Bull. Cancer/Radiother.*, 1990, 77; 69-76
92. J.P. Le Bourgeois, **F. Geara**, P. Piedbois, E. Haddad, E. Levy, A. Taghian, C. Sagna. Radiotherapy of epidemic kaposi's sarcoma in patients with aids. Analysis of 149 cases treated by extended and/or localized cutaneous irradiation. *Ann. Dermatol. Venerol*, 1990, 117; 17-21
93. J.P. Le Bourgeois, **F. Geara**, J.M. Pavlovich. "Complications des irradiations thoraciques." *Gazette Médicale*, 1989, (65), 13-20 (invited article)
94. **Fady Geara**, J.P. Le Bourgeois, P. Piedbois, E. Haddad, E. Levy, A. Taghian. Radiotherapy of kaposi's sarcoma in AIDS. *Ann. Radiol.*, 1989, 32 (2); 112-116
95. J.P. Le Bourgeois, E. Levy, E. Haddad, **F. Geara**, G. Marinello. Total cutaneous electron beam therapy of mycosis fungoides. *Ann. Dermatol. Venerol.*, 1989, 116; 213-217
96. J.P. Le Bourgeois, **F. Geara**, J.M. Pavlovich, P. Piedbois. "Sarcome de Kaposi et radiothérapie." *Médecine Générale*, 1989, (65), 13-20 (invited article)
97. J.P. Le Bourgeois, E. Levy, E. Haddad, **F. Geara**, G. Marinello. Cutaneous lymphomas. *Ann. Radiol.*, 1988, 31 (7-8); 455-464
98. **F. Geara**, G. Calais. "Toxicité cardiaque de la chimiothérapie anti-cancéreuse. Place et rôle de l'échographie." *Rev. Med. Tours*, 1987, 5; 40-45.

Conference presentations and published abstracts

1. **Geara FB**, Eid T, Zouain N, Thebian R, Andraos Th, Chehab Ch, Ramia P, Youssef B, Zeidan Y. Randomized, Prospective, Open-Label Phase III Trial Comparing Mebo® Ointment With Biafine® Cream For The Management of Acute Dermatitis During Radiotherapy For Breast Cancer. GAP 2018 conference Stockholm, Sweden May 14-17, 2018
2. **Fady B. Geara**, *The best of ASCO conference, Beirut, Lebanon, September 2016.*
Presenting: D. Gomez, *et al.* Local Consolidative Therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study.
3. **Fady B. Geara**, *The best of ASCO conference, Beirut, Lebanon, September 2016.*
Presenting: Liao X. Zhongxing, *et al.* Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.
4. **Fady B. Geara**. Nadir PSA alone or in combination with baseline PSA improves prediction of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy with androgen deprivation. GAP 2016 Conference São Paulo, April 24-28, 2016.
5. **Fady B. Geara** Nasopharyngeal cancer treated by induction chemotherapy and definitive radiation: Impact of chemotherapy response on outcome. GAP 2013 Conference. Houston, April 3-5, 2013.
6. **Fady B. Geara**. Radiotherapy in treatment of NPC in young individuals. Proceedings of the 2nd regional congress of Cancer & Blood diseases of Childhood, Amman Sep. 6-8, 2007.
7. **Fady Geara** A phase II Randomized trial comparing radiotherapy with concurrent weekly Cisplatin or weekly Paclitaxel in Patients with advanced cervical Cancer. Proceedings of the Middle East and North Africa (MENA) Cancer Research Conference, September 3-4, 2007.
8. **Fady Geara** Initial Clinical Presentation correlates with survival of patients with glioblastoma multiforme. Proceedings of the Middle East and North Africa (MENA) Cancer Research Conference, September 3-4, 2007.
9. Bulbul MA, Bou Diab N, Hout Y, Hijeij A, Tawil A, **Geara F**. Immediate adjuvant radiation and hormonal therapy for positive surgical margins following radical prostatectomy: selection criteria and outcome. Proceedings of the 29th congress of the Societe internationale d'Urologie. September 2-6, 2007.

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

10. **Fady Geara**, Elie Nasr, Susan Tucker, Emile Brihi, George Zaytoun, Ziad Salem, Nagi El Saghir, Ali Shamseddine, Philip Issa. Nasopharyngeal Cancer in the Middle East: Experience of the American University of Beirut Medical Center. Proceedings of the Middle East and North Africa (MENA) Cancer Research Conference, September 3-4, 2007.
11. **Fady B. Geara**. Cancer epidemiology, registries and inventory of technical structures for cancer care in the Mediterranean area (II) Middle East, Lebanon, April. 28-29, 2007.
12. **Fady B. Geara**. Treatment of Early Stage Prostate Cancer: Surgery vs. Radiotherapy. Proceedings of the 16th Annual NEMROCK conference, Cairo, December 2006
13. **Fady B. Geara**. The Role of Radiotherapy in Non-disseminated Lung Cancer (SCLC and NSCLC). Proceedings of the 16th Annual NEMROCK conference, Cairo, December 2006
14. **F. Geara**, *The best of ASCO conference, Beirut, Lebanon, November 2006*.
Presenting: R. Fietkau, C. Lautenschläger, R. Sauer, J. Dunst, Becker. M. Baumann, T. Wendt, K. Grünschow, C. Hess, V. Budach, H. Iro. Postoperative concurrent chemoradiotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3.
15. **Fady B. Geara**. *The best of ASCO conference, Beirut, Lebanon, November 2006*.
Presenting: A. H. Wolfson, M. F. Brady, R. S. Mannel, Y. Lee, R. J. Futoran, D. Cohn, O. B. Ioffe. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide-mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus.
16. **Fady B. Geara**. Clinical Issues in Radiotherapy for Breast Cancer. *The 3rd International Oncology Conference, Mansoura University, Sharm Elshikh, Egypt, September 2006*
17. **Fady B. Geara**. Novel Approaches in Radiation Therapy for Rectal Cancer. *The 3rd International Oncology Conference, Mansoura University, Sharm Elshikh, Egypt, September 2006*
18. Dabaja B, Comair Y, El-Bondack S, Eid T, Rubeiz J, Nassif S, **Geara F**. Initial clinical presentation correlates with survival of patients with glioblastoma multiforme. *Perspectives in Central Nervous System Malignancies II, Budapest Hungary, April 2006*
19. **F. Geara**, A.Khalil, A. Shamseddine, M. Charafeddine, M. Seoud. A Phase II Randomized Trial Comparing Radiotherapy (RT) with Concurrent Weekly Cisplatin to RT with Weekly Paclitaxel in Patients with Advanced Cervical Cancer. *Radiological Society of North America Scientific Assembly and Annual Meeting Program. McCormick Place, Chicago, USA. November 2005*
20. P. Fernainy, **Fady Geara**, W. Itani, J. Haykal, M. Haddadin, H. Gali-Muhtasib. Molecular Mechanisms of the Radiosensitizing Effects of a Quinoxaline Dioxide Derivative. *The 52nd Radiation Research Society Meeting, Denver Colorado, October 2005*
21. A.Khalil, A. Shamseddine, **F. Geara**, M. Charafeddine, M. Seoud. Concurrent chemoradiotherapy for locally advanced cervical cancer: A prospective randomized trial comparing cisplatin vs. paclitaxel. *The American Society of Clinical Oncology Annual Meeting, Orlando, May 2005*.
22. M. Seoud, J. Abbas, M. Khalil, M. Charafeddine, Z. Salem, N. El-Saghir, **F. Geara**, A. Shamseddine; Clinical characteristics of breast cancer patients diagnosed and treated at the American university of Beirut medical center from 1990 to 2001. *The American Society of Clinical Oncology Annual Meeting, Chicago, May 2003*.
23. Ghali-Muhtasib H, Sidani M, Diab-Assaf M, Haddadin M, **Geara F**, Zaatari G. An evaluation of the radiosensitization effects of Quinoxaline 1,4-Dioxides. *The Second International Conference on Translational Research in Radiation Oncology, Lugano Switzerland, March 2003*
24. **F. B. Geara**, E. Nasr, S. L. Tucker, K. Bikhazi, J. Abbas, Z. Salem, N. ElSaghir, A. Shamseddine, P. Issa. Results Of Adjuvant Radiotherapy Alone And Combined Modality Therapy For High Risk Breast Cancer Patients With 10 Or More Positive Axillary Lymphnodes. *International Congress of Radiation oncology (ICRO), Januray 2001, Melbourne, Australia*
25. N. El Saghir, A. Shamseddine, **F. B. Geara**, A. Tawil, A. Taher, Z. Salem, A. Khalil, and M. Seoud. Age Distribution of Breast Cancer in Lebanon: Analysis of 2282 cases from the American University of Beirut Medical Center. *The American Society of Clinical Oncology Annual Meeting, San Fransisco, May 2001*.
26. Khauli RB, Bulbul M, Wazzan W, Hijaz A, Nasr R, Freiha F, Haddad M, **Geara F**, Tawil A Radical Retropubic Prostatectomy: Association of Conventional Clinical Parameters and PSA Indexes in Extraprostatic Disease and Micrometastasis. *The American Urologic Association Anaheim, California, June 2001*
27. Nagi El-Saghir, Hassan Jaafar, Ayman Tawil, Ziad Salem, Ali Taher, Ali Bazarbachi, **Fady Geara**, Varant Aznavourian, Myrna Abbas, Nina Shabb, Mohieddin Seoud, Ali Shamseddine Lymphoma in the Middle

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

- East: Review of 1115 Cases of the Tumor Registry of the American University of Beirut Medical Center (AUBMC) in Lebanon. *The American Society of Clinical Oncology Annual Meeting, May 2000.*
28. Hourani M., Zaytoun G., Hammoud D., **Geara F.B.**, Al-Kutoubi A.M. Use of sestamibi SPECT in detection of recurrent laryngeal cancer. European Society of Nuclear Medicine, Annual Meeting, Vienna, March, 2000.
 29. **F.B. Geara**, E. Nasr, S.L. Tucker, G. Zaytoun, E. Brihi, Z. Salem, N. Saghir, A. Shamseddine, P. Issa. Nasopharyngeal Cancer (NPC) In The Middle East: Experience Of The American University of Beirut Medical Center. *European Society for Therapeutic Radiology and Oncology (ESTRO), Istanbul, September 2000.*
 30. **Fady B. Geara**. Advances in the therapy of Nasopharyngeal cancer. *Middle East Medical assembly, 34th annual meeting, Beirut, Lb; May 1999*
 31. Ang KK, Trotti A, Garden AS, Foote RL, Morrison WH, **Geara FB**, Klotch W, Peters LJ, Goepfert H. Impact of Risk Factors and Total Time of Surgery plus Radiotherapy on the Outcome of Patients with Advanced Head and Neck Cancer. *American Society for Therapeutic Radiology and Oncology (ASTRO), San Antonio, October 1999*
 32. **Fady B. Geara**. Status of Radiotherapy for Prostate Cancer. *The XXXIII Middle East Medical Assembly, American University of Beirut, Beirut Lebanon, May 1998*
 33. **Fady B. Geara**. Advances in Radiation Therapy for Brain Tumors. *The XXXIII Middle East Medical Assembly, American University of Beirut, Beirut Lebanon, May 1998*
 34. W.A. Brock, E. Abozina; S.P. Lankford; **F.B. Geara**. Human Diploid Fibroblasts undergo Terminal Differentiation/Senescence with minimal cell loss in response to low doses of ionizing radiation. *6th International Meeting on Progress in Radio-oncology; Salzburg, Austria; May 1998*
 35. S. L. Tucker; **Fady B. Geara**; G. Sanguineti; A. S. Garden; L. J. Peters; and K. K. Ang. The interrelationships among local recurrence, neck recurrence, and distant metastasis in carcinoma of the nasopharynx. *European Society for Therapeutic Radiology and Oncology (ESTRO), Edinburg, September 1998*
 36. **Fady B. Geara**; G. Sanguineti; R. Suki; A. S. Garden; S. L. Tucker; W. H. Morrison; L. J. Peters; and K. K. Ang. Is There A Difference In The Clinical Features And Treatment Outcome Of Nasopharyngeal Cancer Between Asian And Caucasian Patients? *International Congress of Radiation Oncology, Beijing, China, June 1997*
 37. Scott P. Lankford, **F. B. Geara**, W.A. Brock. *In Vitro Irradiation Of Early Passage Human Fibroblasts Induces Senescence-Associated β -Galactosidase Activity American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, October 1997*
 38. Maor, M.H.; Dubey P.; **F.B.Geara**, et al. Stereotactic radiosurgery for brain metastases: Results and prognostic factors. *Int. J. Rad. Onc. Biol. Phys. 39; 228: 1997. American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, October 1997*
 39. **Fady B. Geara**; G. Sanguineti; B. S. Glisson; S. L. Tucker; A. S. Garden; K. K. Ang; H. Goepfert; L. J. Peters; and W. K. Hong. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in advanced nasopharyngeal carcinoma: results of a matched cohort study. *IVth Rome International Symposium on Cancer Treatment; Chemotherapy and Radiotehrapy: An Integrated Approach, Rome, Italy, June 1996*
 40. **Fady B. Geara**; G. Sanguineti; A. S. Garden; S. L. Tucker; B. S. Glisson; S. M. Lippman; K. K. Ang; G.L. Clayman; H. Goepfert; W. K. Hong; L. J. Peters. Evidence for a positive role for chemotherapy in advanced nasopharyngeal carcinoma: results of a matched cohort study. *4th International Conference on Head and Neck Cancer, Toronto, July 1996*
 41. **Fady B. Geara**; R. Komaki, S. L. Tucker, P. Perkins, E. L. Travis; and J. D. Cox. Determinants of lung fibrosis after chemoradiation for small cell carcinoma of the lung: Evidence for inherent interindividual variation. *American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, October 1996.*
 42. **Fady B. Geara**, G. Sanguineti, S. L. Tucker, A. S. Garden W.H. Morrison, L. J. Peters, and K.K. Ang. Prognostic Determinants of Nasopharyngeal Cancer Treated by Radiotherapy Alone: Results of a Multivariate Analysis on 378 Patients. *European Society for Therapeutic Radiology and Oncology (ESTRO), Vienna, Austria, September 1996*

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

43. **Fady B. Geara**, K. K. Ang, L. J. Peters, A.S. Garden, L. Levy, B. W. Brown. Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. *American Radium Society, Paris, April 1995*
44. A.S. Garden, W.H. Morrison, K. K. Ang, **F. B. Geara**, L. J. Peters. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? *American Society for Therapeutic Radiology and Oncology (ASTRO), Miami Beach, October 1995.*
45. S. L. Tucker, **F.B. Geara**, L.J. Peters, W.A. Brock, How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? *American Society for Therapeutic Radiology and Oncology (ASTRO), Miami Beach, October 1995*
46. A. Taghian, **F. Geara**, W. Dahlberg, D. Gioioso, J. Wike, K. Tomkinson, J. B. Little, W.A. Brock, H. D. Suit. Inter-researcher, inter-laboratory, and inter-technique variations in the determination of SF2 of human tumor cell lines. *Radiation Research Society, Annual Meeting, Nashville, TN, May 1994*
47. **F. B. Geara**. Intrinsic normal cell radiosensitivity as a determinant of clinical radiation tolerance. (Invited speaker abstract) *Radiation Research Society, Annual Meeting, Nashville, TN, May 1994*
48. W. A. Brock, S. Tucker, I. Turesson, **F. B. Geara**, J. Wike, J. Nyman, L.J. Peters. Fibroblast radiosensitivity versus acute and late normal tissue responses in patients treated for breast cancer. *American Society for Therapeutic Radiology and Oncology (ASTRO), San Francisco, October 1994.*
49. **F. B. Geara**, G. K. Zagars, A. Pollack. The value of transrectal ultrasound in the new TNM staging system for prostate cancer patients receiving definitive radiotherapy. *Radiological Society of North America (RSNA), Chicago, December 1994*
50. **F. B. Geara**. Intrinsic normal cell radiosensitivity as a determinant of normal tissue tolerance to radiotherapy. (invited panelist) *American Society for Therapeutic Radiology and Oncology (ASTRO), San Francisco, October 1994.*
51. **F. B. Geara**, L.J. Peters, and W.A. Brock. *In vitro* normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. *Radiation Research Society, Annual Meeting, Dallas, March 1993*
52. W.A. Brock, **F. B. Geara**, L.J. Peters. Cellular radiosensitivity as a predictor of radiotherapy response. *International Congress of Radiation Oncology, Kyoto, Japan, 1993*
53. J.P. Le Bourgeois, H. Frikha, C. Le Pechoux, P. Piedbois, **F. Geara**, E. Haddad, M. Ghilezan, J.J.Mazeron. Radiotherapy in the management of epidemic Kaposi's sarcoma. An experience on 4565 courses of treatment in 400 patients. *International Congress of Radiation Oncology, Kyoto, Japan, 1993*
54. **F. Geara**, L.J. Peters, K.K. Ang, J.L. Wike, and W.A. Brock. Comparative Radiosensitivity of human lymphocytes and fibroblasts. *Radiation Research Society, Annual Meeting, Salt Lake City, March 1992*
55. W.A. Brock, **F. B. Geara**, L.J. Peters. Cellular radiosensitivity as a predictor of radiotherapy response. *In proceedings of the third International Conference on Head and Neck Cancer, San Francisco, CA, Elsevier Science, 1992*
56. W.A. Brock, **F. B. Geara**, L.J. Peters. *In vitro* radiosensitivity of primary and early passage squamous cell carcinomas versus local tumor control. *In proceedings of the Fourth International Conference on Dose, and Fractionation in Radiotherapy, Madison, Wisconsin, 1992*
57. **F. B. Geara**, L.J. Peters, K.K. Ang, M.D. Mc Neese, J.L. Wike, D. Callender, W.A. Brock. Prospective comparison between *in vitro* normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. *American Society for Therapeutic Radiology and Oncology (ASTRO), San Diego, November 1992*
58. **F. B. Geara**, L.J. Peters, and W.A. Brock. *In vitro* normal cell radiosensitivity: a potential predictor of normal tissue reactions in patients undergoing radiotherapy. *Radiological Society of North America (RSNA), Chicago, December 1992*
59. **F. Geara**, J.P. Le Bourgeois, C. Lepechoux, P. Piedbois, J.M. Pavlovitch, J.J.Mazeron. Radiotherapy of mucosal and cutaneous epidemic Kaposi's sarcoma (EKS): a report on 285 patients. *American Society of Clinical Oncology (ASCO), Houston, May 1991.*
60. **F. Geara**, L.J. Peters, K.K. Ang, J.L. Wike, S.L. Sivan, D. Callender and W.A. Brock. *In vitro* radiosensitivity of human lymphocytes, fibroblasts and keratinocytes after high and low dose-rate irradiation. *9th International Congress of Radiation Research, Toronto, July 1991.*
61. W.A. Brock, F.L. Baker, **F. Geara**, H. Goepfert, L.J. Peters. *In vitro* radiosensitivity of tumor cells and local tumor control by radiotherapy. *9th International Congress of Radiation Research, Toronto, July 1991.*

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

62. **F. Geara**, T. Girinski, N. Chavaudra, J.M. Cosset, B. Dubray, W.A. Brock, E.P. Malaise. Estimation of clonogenic cell fraction in primary cultures derived from squamous cell carcinomas. *Radiation Research Society, Annual Meeting, New Orleans, April 1990*
63. **F. Geara**, J.P. Le Bourgeois, P. Piedbois, J.M. Pavlovitch, J.J.Mazeron. Radiotherapy in the management of AIDS related epidemic Kaposi's sarcoma. *American Society for Therapeutic Radiology and Oncology (ASTRO), Miami, October 1990.*
64. T. Girinski, **F. Geara**, N. Chavaudra, J.M. Cosset, W.A. Brock, E.P. Malaise. Primary cultures from human tumor biopsies. *International Symposium in Chemoresistance and Radioresistance, Paris, July 1989*
65. **F. Geara**, G. Calais. "Radiotherapie exclusive dans le traitement des cancers oesophagiens. Analyse des resultats et des facteurs pronostiques. " *Annual Meeting in Radiology-Radiotherapy, Paris, 1987*

C. Teaching

Invited lecturer

1. Update on the management of prostate cancer, ESO Latin America Masterclass in Clinical Oncology, **Mexico**; April 2018
2. Radiation management of cervical and endometrial cancer, ESO Latin America Masterclass in Clinical Oncology, **Mexico**; April 2018
3. Updates on the management of nasopharyngeal cancer. 1st Lebanese American University Head and Neck symposium; **Beirut** 2018
4. New Trends in Radiation Therapy for Breast Cancer; 10th BGICC (Breast, Gynecology, and Immunotherapy Conference). **Cairo** 2018
5. Challenges in Radiation Therapy Carcinoma of the Cervix; 10th BGICC (Breast, Gynecology, and Immunotherapy Conference). **Cairo** 2018
6. Radiotherapy for lung Cancer, ESO South Mediterranean course, **Limassol, Cyprus**, December 2017
7. Indications of radiation therapy after neoadjuvant systemic therapy in breast cancer. 20th Annual International Scientific Conference of Alexandria Clinical Oncology Department (ACOD). **Alexandria Egypt**, 2017
8. Radiotherapy of Head and Neck Cancer, 4th Masterclass In Clinical Oncology , **Tbilisi, Georgia**, October 2017
9. Challenges in postmastectomy radiation therapy. Annual meeting of the Jordanian Oncology Society, **Amman Jordan** October 2017
10. Therapeutic management of rectal cancer, ESO Masterclass in Clinical Oncology, **Moscow, Russia**; April 2017
11. Update on the management of prostate cancer, ESO Latin America Masterclass in Clinical Oncology, **Costa Rica**; April 2017
12. Radiation management of cervical and endometrial cancer, ESO Latin America Masterclass in Clinical Oncology, **Costa Rica**; April 2017
13. Combination of Immunotherapy and Radiation in Cancer Therapy, the 4th course of angiogenesis with recent advances in Immunotherapy, (AUBMC-MSKCC); **Beirut, Lebanon**; February, 2017
14. Radiotherapy of Cervical and endometrial Cancer, ESO course on gynecological and urogenital cancers, **Tbilisi, Georgia**, November 2016
15. Local therapy of bladder cancer, ESO course on gynecological and urogenital cancers, **Tbilisi, Georgia**, November 2016
16. State Of The Art Treatment For Breast Cancer In 2016, Emirates Oncology Conference, **Abu Dhabi, UAE**, November, 2016
17. Breast Local Therapy, Debate: Radiotherapy boost versus no Boost, Invited speaker , Bridging gaps in oncology, **Cairo, Egypt**, November 2016
18. Panel Discussion, Triple negative BC, Bridging gaps in oncology, **Cairo, Egypt**, November 2016
19. Head & Neck Panel Discussion, Locally Advanced Head & Neck Cancers the Debates and Controversies, Bridging gaps in oncology, **Cairo, Egypt**, November 2016

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

20. Indications of Radiotherapy post neoadjuvant systemic therapy , 19th Annual International Scientific
21. Conference of Alexandria Clinical Oncology Department (ACOD), Alexandria, Egypt, November, 2016
22. The role of radiotherapy in the management of rectal and anal cancer, 5th ESO Arab countries masterclass in clinical oncology, Cairo, Egypt, October 2016
23. Indications of radiation therapy in early breast cancer, 5th ESO Arab countries masterclass in clinical Oncology, Cairo, Egypt, October 2016
24. Controversies in postmastectomy and regional radiation therapy, women oncology conference, Amman, Jordan; October, 2016
25. Non Operative Management in Rectal Cancer: A matter of Debate: Radiotherapy Perspective, Spotlights in Oncology: Leading Survival in Colorectal Carcinomas, Beirut, Lebanon; September 2016
26. Insights from the region: interventions in management of bone metastases, Amgen Oncology Bone and Supportive Care Summit: BASiCS, Dubai, UAE; May 2016.
27. Overview of Radiation Oncology Techniques in locally advanced SCCHN, Spotlights in Oncology: Leading Survival in Head & Neck Colorectal Carcinomas, Beirut, Lebanon; May 2016.
28. Locally advanced SCCHN: Optimizing treatment and improving Quality of Life, Spotlights in Oncology: Leading Survival in Head & Neck Colorectal Carcinomas, Beirut, Lebanon; May 2016.
29. Role of Radiation Oncology in rectal cancer, Spotlights in Oncology: Leading Survival in Head & Neck Colorectal Carcinomas, Beirut, **Lebanon**; May 2016.
30. Therapeutic management of rectal cancer, ESO Masterclass in Clinical Oncology, **Moscow, Russia**; April 2016
31. Advanced Cervical Cancer: Concurrent Chemo-Radiotherapy, 4th Lebanese Gynecologic Oncologic Group Annual Meeting, **Beirut, Lebanon**; April 2016
32. New Technologies for brain radiation and what it adds to the discussion of localized radiation vs. whole-brain radiation, GAP Conference, **São Paulo, Brazil**; April 2016
33. The new potential for radiation therapy in management of prostate cancer, GI/GU Oncology Conference, **Amman, Jordan**; April 2016,
34. Optimizing radiation and androgen ablation in prostate cancer, 2nd Astellas MENA/SSA Oncology & Hematology Summit, **Dubai, UAE**; March 2016
35. Partial Breast Irradiation, 7th annual international conference, **Luxor, Egypt**; February 2016,
36. Setups and Research in Breast Radiation Therapy in the Middle East, Beirut Breast Cancer Conference 4, **Beirut, Lebanon**; February 2016
37. State of the art Radiation Oncology: Technology helping Biology, AUB Presidential Symposium Cancer in the Molecular Era: Promise and Prospects, **Beirut, Lebanon**; January 2016
38. When to consider post-mastectomy radiation therapy in EBC. Breast Cancer Master Class, **Dubai, UAE**; December, 2014.
39. Genetic Radiosensitivity Syndromes. Symposium of Radiobiology, Radiopathology, and Radioprotection, **Beirut Lebanon**; November 2015;
40. Radiotherapy of Breast Cancer. ESO Masterclass In Clinical Oncology, **Tbilisi, Georgia**; October 2015
41. Radiotherapy of Lung Cancer. ESO Masterclass In Clinical Oncology, **Tbilisi, Georgia**; October 2015
42. The 10th Best of ASCO, Beirut Lebanon. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast, **Beirut Lebanon**; September 2015
43. The 10th Best of ASCO, Beirut Lebanon. A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. **Beirut, Lebanon**; September 2015
44. Radiotherapy techniques of esophageal cancer. 4th International Gastrointestinal and Liver Oncology Conference[IGILOC] **Cairo, Egypt**; May 2015
45. Non-surgical management in rectal cancer. 4th International Gastrointestinal and Liver Oncology Conference[IGILOC] **Cairo, Egypt**; May 2015
46. Radiation Therapy and Breast Reconstruction. The 3rd American University of Beirut Breast Cancer Symposium. **Beirut, Lebanon**; February 2015
47. Principles of Radiotherapeutic Management of Early BC. Breast Cancer Master Class. **Dubai, UAE**; December 2014.
48. Gaps and Disparities in Breast cancer radiation therapy: Bridging the Gap. San Antonio Breast Cancer Symposium; AROME satellite symposium, **San Antonio TX**; 2014.

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

49. From HDR to IMRT: What is new? The 18th International Annual meeting of the Lebanese Society of Obstetrics and Gynecology and the 2nd course of the Ian Donald Inter-University school of Medical Ultrasound. **Beirut, Lebanon**; November 2014
50. Organ preservation in rectal cancer: An update. The 9th International Jordan Oncology Society Conference **Amman, Jordan**; October 2014
51. Overview of radiation therapy for genitourinary malignancies. Second Joint MSKCC/AUB/HMC/WCMC-Q Course in Oncologic Sciences, **Doha Qatar**, October 2014
52. Basics of Radiation Therapy;
53. Radiation Therapy for Head and Neck Cancer;
54. Radiation Therapy for Breast Cancer;
55. Radiation therapy for gynecological malignancies;
The 10th ESO-ESMO course on Oncology for Medical Student. Course Faculty; **Ioannina, Greece** 20-26, 2014.
56. Radiation treatment of lung cancer: an update. 4th Euro Arab School of Oncology (EASO) masterclass in clinical oncology, **Casablanca, Morocco**; June 2014
57. Indications of radiation therapy in early breast cancer. 4th Euro Arab School of Oncology (EASO) masterclass in clinical oncology, **Casablanca, Morocco**; June 2014
58. Radiation therapy in early breast cancer: another tool to improve survival. Advances in the Management of Early Breast Cancer. Sandoz Oncology Expert Forum. **Salzburg –Austria**, April, 2014
59. De-escalation in breast cancer radiation therapy. The 2nd American University of Beirut Breast Cancer Symposium. **Beirut, Lebanon**, Feb 2014
60. Principles of radiotherapy of early Breast Cancer. Masterclass, **Dubai**, December 21-22, 2013
61. Radiotherapy for advanced prostate cancer. Lebanese society of Urology. **Beirut**, Phoenicia Hotel, October 31, 2013.
62. The European Arab School of Oncology (EASO) course on Lights and Shadows in the Management of Prostate Cancer. Focal Therapies; **Marrakesh**, October 2013
63. Basics of Radiation Therapy;
64. Radiation Therapy for Head and Neck Cancer;
65. Radiation Therapy for Breast Cancer;
66. Radiation therapy for gynecological malignancies;
The 10th ESO-ESMO course on Oncology for Medical Student. Course Faculty; **Ioannina, Greece** 20-26, 2013.
67. The 8th Best of ASCO 2013 in Lebanon. Tailoring radiation recommendations based on breast subtypes and other risk factors. **Beirut, Lebanon** June 21-22, 2013.
68. Cancer du Sein sans atteintes ganglionnaires à haut risque: la radiothérapie des aires ganglionnaires doit elle être systématique? La 10^{ème} édition du cours supérieur francophone de Sénologie, **Essaouira, Morocco**, Mai 17-18, 2013
69. The Arab Collaborative Hematology & Oncology Group (ACHOG) Angiogenesis course. Radiotherapy and Angiogenesis. **Algiers, Algeria**, May 4, 5 2013.
70. The Lebanese Society of Medical Oncology & Hematology-Oncology Department of Hotel Dieu de France. Cervical Cancer: Are we making any progress? April 19-20, 2013
71. Biomodulation of radiation therapy with Erbitux for locally advanced H&N cancer. “ MerckSerono Oncology Symposium – **Prague**; April 2013.
72. The MD Anderson Cancer Center Global Academic Program annual conference (GAP 2013). Nasopharyngeal cancer treated by induction chemotherapy and definitive radiation: Impact of chemotherapy response on outcome. **Houston, TX**, April 3-5, 2013.
73. American University of Beirut workshop on Acromegaly. Role of Radiotherapy in the treatment of Acromegaly. **Beirut**, March 15-16, 2013.
74. The Gulf thoracic Congress 2013. Lung Cancer management; **Dubai**, March 13-16, 2013.
75. The Arab Collaborative Hematology & Oncology Group Fighting Cancer through Capacity Building course on Angiogenesis. Radiotherapy and angiogenesis. **Istanbul**, February 22-23, 2013.
76. The second Uro-Oncology winter symposia “Highlights in Uro-Oncology”: T2/T3 Bladder Cancer: Surgery Vs Chemoradiotherapy. **Beirut**, February 16, 2013.

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

77. The MD Anderson Cancer Center Regional Global Academic Program conference on Genitourinary malignancies. Adjuvant and salvage therapy after radical prostatectomy. January 31- February 1, 2013; **Amman Jordan**.
78. American University of Beirut First Breast Cancer Conference: Case discussion. February 8-9, 2013.
79. Best of San Antonio breast cancer symposium. The UK START (standardization of breast radiotherapy) trials: 10-year follow up results. **Riyadh, Saudi Arabia**; January 15-16, 2013.
80. Principles of radiotherapeutic management of breast cancer, Breast cancer masterclass, **Beirut**, December 21-22, 2012
81. Locally advanced PC. EASO Prostate Cancer Educational Program, November 23, 2012.
82. Controversies in the adjuvant treatment of pancreatic cancer (chemotherapy vs chemo radiation). Emirates Oncology conference 8-10 November 2012. **Abu Dhabi, UAE**.
83. Biomodulation of radiation therapy with Erbitux for locally advanced H&N cancer. “ MerckSerono Oncology Symposium – **Muscat – Oman**, October 18-20, 2012.
84. Basics in Radiation Oncology. “9th ESO-ESMO course on Oncology for medical students”. July 21-27, 2012
85. Basics of Radiation Therapy;
86. Radiation Therapy for Head and Neck Cancer;
87. Radiation Therapy for Breast Cancer;
88. Radiation therapy for gynecological malignancies;
The 10th ESO-ESMO course on Oncology for Medical Student. Course Faculty; **Ioannina, Greece** 20-26, 2012.
89. Definitive radiotherapy for localized and local advanced PCa, “Master class review in Urology 2012” **Beirut**, Lebanon; July 11, 2012
90. Moderator at The 1st Lebanese American University and Rizk Hospital conference jointly held at the 12th International American Lebanese Medical Association Congress “Healthcare beyond borders” for the session “Advances in Oncology”; **Beirut**, June 2012
91. Presenting: McCormick, A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). The best of ASCO, 2012, **Beirut – Lebanon**,
92. “Head and Neck Radiotherapy” Department of Otolaryngology Head and Neck surgery. **Beirut**, Lebanon; February 27, 2012.
93. Challenging cases in breast cancer: DCIS. The Lebanese Medical Oncology Society annual meeting, **Beirut** Lebanon, April 2012
94. Advances of Radiation Therapy of Lung cancer. “MENA NCCN Regional Meeting” Jan. 26-28, 2012 **Doha, Qatar**.
95. Update on partial breast irradiation. The 14th annual international clinical oncology conference. **Alexandria, Egypt**; October 2011
96. Re-irradiation for lumpectomy treated patients, is it feasible? The 14th annual international clinical oncology conference. **Alexandria, Egypt**; October 2011
97. Presenting: K. Kian Ang, M.D., Ph.D. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). The 5th best of ASCO July 2011, **Beirut – Lebanon**
98. Presenting: T. Whelan MD. Patterns of relapse and toxicity in NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. The 5th best of ASCO July 2011, **Beirut – Lebanon**.
99. Optimizing Androgen blockade and radiation therapy for localized prostate cancer: The AUB current practice protocol. Global Academic Conference. The University of Texas MD Anderson Cancer Center, **Houston, TX**; May 31 – June 2, 2011
100. The role of IMRT in the treatment of complex soft tissue sarcoma - Middle East Medical Assembly. **Beirut** Lebanon, May 5-8, 2011.
101. The 5th Middle East Best of CTSC - AACR San Antonio Breast Cancer Symposium January 12 - 13, 2011. **Riyadh, KSA**
102. Short radiotherapy versus classical fractionation. International Congress for Cancer in Young Women. Sep 30-Oct.01-02, 2010. **Damascus, Syria**.
103. New trends of radiotherapy in early stage breast cancer. The 7th International Jordan Oncology Society Conference. **Jordan** July 29-31, 2010.

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

104. Neoadjuvant radiotherapy for rectal cancer. XIXth congress of surgery, Safadi cultural center, **Tripoli, Lebanon**. May 14-15, 2010.
105. Radiotherapy in prostate cancer, the 10th Pan Arab Congress, Algiers April 30 – May 2, 2010,
106. Radiotherapy for locally advanced bladder cancer, the 10th Pan Arab Congress, **Algiers** April 30 – May 2, 2010,
107. Local management issues after preoperative systematic therapy for operable breast cancer, **Riyadh, KSA**, International symposium on new frontiers in breast cancer
108. Updated results and guidelines for radiation therapy post breast conserving surgery, **Riyadh, KSA**, International symposium on new frontiers in breast cancer
109. Use of post mastectomy radiation therapy in operable breast cancer. **Riyadh, KSA**, International symposium on new frontiers in breast cancer
110. Panelist: Mock IRB – IRB review of a multi-center International clinical trial, Global Academic Programs conference 2010, **Houston, Texas** April 13-16, 2010
111. Combined modality therapy for locally advanced HNC, The Winter academy, **St. Moritz & Pontresina, Switzerland**; April 8-11, 2010
112. Update on Radiotherapy for Prostate Cancer. European Arab School of Oncology (EASO), **Amman, Jordan** October 2009.
113. Radiotherapy for Bladder Cancer. European Arab School of Oncology (EASO), **Amman, Jordan** October 2009.
114. Malignant Lymphomas: The New Challenges In Radiation Management. 18th annual conference NEMROCK: **Cairo**, September 2009.
115. Presenting: Tjan-Heijnen, V. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0(i+)) in the sentinel lymph node (SN): results from the MIRROR study. The 3rd best of ASCO July 2009, Beirut – Lebanon.
116. Presenting: Dueñas-González, A. A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix The 3rd best of ASCO July 2009, Beirut – Lebanon.
117. Presenting: Overgaard, J. Randomized study of Aranesp as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - Final outcome of the DAHANCA 10 trial. The 3rd best of ASCO July 2009, Beirut – Lebanon.
118. Radiotherapy for early lung cancer. The 9th PAN-ARAB Cancer Congress Cairo May 2009
119. Updates on radiation therapy for Breast Cancer. Review of the Saint Galen Consensus Conference. **Bahrain**, April 2009
120. Optimizing the Use of Chemoradiation in Cancer Management. Medicine Grand Round, American University Of Beirut, April 2009
121. Multimodality management of T3-T4 laryngeal cancer. The Annual Meeting of the Lebanese Society of otolaryngology Head and Neck surgery. March 20-21, 2009
122. Clinical research and inventory of means around the MA. AROME meeting, **Budva Montenegro**.
123. The rationale and evidence for using concurrent chemoradiation in cancer management. The 6th international Jordan Oncology Society Conference; **Amman Jordan**
124. Does radiation eliminate the need for lymph node dissection in endometrial cancer? The 3rd meeting of the federation of Gyn-Ob Societies of the Mediterranean, the annual meeting of the Lebanese society of Ob Gyn in collaboration with Arab federation of Ob Gyn societies and FGOLF. Oct 30-Nov 1, 2008 Movenpick Hotel, **Beirut** – Lebanon.
125. Presenting: Loehrer, P. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E420 The 3rd best of ASCO 2008, **Beirut** – Lebanon.
126. Presenting: Le Pêchoux, C. Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis. The 3rd best of ASCO 2008, **Beirut** – Lebanon.
127. Arab Medical Association Against Cancer: Early Cancer from Prevention to Cure. **Syria**, April 3-5, 2008
128. L'association radio-chimiothérapie exclusive des cancers localement avancés de l'oesophage. 8ème biennale Monégasque de cancérologie. **Monaco**, 23-26 Janvier 2008.

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

129. Contemporary protocols in external beam radiotherapy. Arab health congress. Middle East Urology Update 30-31 January 2008.
130. The best of SABCS conference, **Riyadh, KSA** January 2008.
Presenting: T Whelan. Long-Term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation (AHWBI) Following Breast Conserving Surgery.
131. The best of SABCS conference, **Riyadh, KSA** January 2008.
Presenting: Lori J. Pierce. Radiation Treatment Planning for Breast Cancer: A Journey Through Time.
132. Radiotherapy in treatment of NPC in young individuals. The 2nd regional congress of Cancer & Blood diseases of Childhood, **Amman** Sep. 6-8, 2007.
133. Recent advances in Radiotherapy. The congress of the Lebanese Society of Neurosurgery 7-8 December, 2007.
134. External beam radiotherapy for prostate cancer: Current strategies. 7th congress of Arab Association of Urology, AAU 2007 Beirut Nov. 29 – Dec. 2, 2007.
135. Radiotherapy in treatment of NPC in young individuals. Proceedings of the 2nd regional congress of Cancer & Blood diseases of Childhood, **Amman** Sep. 6-8, 2007.
136. Radiotherapy in treatment of NPC in young individuals. Proceedings of the 2nd regional congress of Cancer & Blood diseases of Childhood, **Amman** Sep. 6-8, 2007.
137. Radiation Therapy for early breast cancer. The XLI Middle East Medical Assembly. May 11-12, 2007.
138. Partial breast irradiation. The XLI Middle East Medical Assembly. May 11-12, 2007.
139. Post-mastectomy irradiation: Status of the evidence. The XLI Middle East Medical Assembly. May 11-12, 2007.
140. Cancer epidemiology, registries and inventory of technical structures for cancer care in the Mediterranean area (II) Middle East, Lebanon, April. 28-29, 2007.
141. Treatment of Early Stage Prostate Cancer: Surgery vs. Radiotherapy. Proceedings of the 16th Annual NEMROCK conference, Cairo, December 2006
142. The Role of Radiotherapy in Non-disseminated Lung Cancer (SCLC and NSCLC). Proceedings of the 16th Annual NEMROCK conference, Cairo, December 2006
143. Clinical Issues in Radiotherapy for Breast Cancer. The 3rd International Oncology Conference, Mansoura University, Sharm Elshikh, Egypt, September 2006
144. Novel Approaches in Radiation Therapy for Rectal Cancer. The 3rd International Oncology Conference, Mansoura University, Sharm Elshikh, Egypt, September 2006
145. State of the Art in Treatment of Small Cell Lung Cancer. The 7th Syrian American Medical Society meeting. Damascus, Syria June 2006
146. Radiotherapy for Breast Cancer. 10th Spring Lebanese Congress of Surgery. Beirut, Lebanon, June 2006.
147. Advances in Radiation Therapy for Brain Tumors. Multidisciplinary Approach for Brain Tumors Conference. Beirut, Lebanon, May 2006
148. Novel approaches in radiation therapy for rectal cancer. The XL Middle East Medical Assembly. Beirut, Lebanon, May 2006
149. Is there a role for prophylactic cranial radiation in localized non-small cell lung cancer? The XL Middle East Medical Assembly. Beirut, Lebanon, May 2006
150. Novel approaches in radiation therapy for rectal cancer. The Fifth Jordan Oncology Society Conference, Jordan, April 2006
151. Hodgkin's disease: the new challenges in radiation management. The Fifth Jordan Oncology Society Conference, Jordan, April 2006
152. A Phase II Randomized Trial Comparing Radiotherapy (RT) with Concurrent Weekly Cisplatin to RT with Weekly Paclitaxel in Patients with Advanced Cervical Cancer. Radiological Society of North America Scientific Assembly and Annual Meeting Program. McCormick Place, Chicago, USA. November 2005
153. Radiation Burns. Lebanese Society of Plastic, Reconstructive & Esthetic Surgery. Annual Mediterranean Council for Burns & Fire Disasters. Beirut, Lebanon. November 2005
154. Radiation Oncology. Biology or Technology? Medical Grand Round. The American University of Beirut Medical Center. Beirut, Lebanon. November 2005
155. Radiation therapy for breast cancer: issues in young woman. The European School of Oncology (ESO) advanced course in breast cancer. Beirut, Lebanon October 2005

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

156. Radiation Therapy: Toward Improved Efficacy and Enhanced Safety. The 6th Syrian American Medical Society meeting. Damascus, Syria June 2005
157. Radiation Therapy for Meningiomas. The Annual Meeting of The Lebanese Neurosurgical Society. Beirut, March, 2005
158. Paradigm shift in Colorectal Cancer Management: Place of preoperative radiotherapy. The Jordanian Oncology Society continuing medical education meeting, The Dead Sea Jordan, February 2005
159. Stereotactic Radiotherapy for Non Small Cell Lung Cancer. 2nd Meeting of the Mediterranean School of Oncology, Alexandria, Egypt; December 2004
160. Incidence of Breast Cancer in Lebanon: Implications for early detection and screening. Conference on Prevention and Early Detection of Cancer. Amman, Jordan, Nov 2004
161. Genetics of Breast cancer: Value of testing for BRCA 1 and BRCA 2. Conference on Prevention and Early Detection of Cancer. Amman, Jordan, Nov 2004
162. Preoperative vs. postoperative radiotherapy for rectal cancer. The Centre Hospitalier du Nord annual conference, Zghorta, October, 2004
163. Adjuvant Radiation therapy for colorectal cancer: Timing and outcome. Gastrointestinal cancer symposium, The Syrian Oncology Society, Damascus, Sept 2004
164. Chemoradiation for limited-stage small cell lung cancer. WHO regional consensus meeting on lung cancer. Cairo, June 2004
165. Radiotherapy for breast cancer: Evidence and Pitfalls. The Tanta Cancer Center annual conference, Alexandria, Egypt, May 2004
166. Nasopharyngeal Cancer in The Middle East. Experience of The American University of Beirut Medical Center. The Jordanian Oncology Society-King Hussein annual conference. Amman, Jordan, April 2004
167. Update on Prostate cancer radiotherapy. The Jordanian Oncology Society-King Hussein annual conference. Amman, Jordan, April 2004
168. Adjuvant radiotherapy for rectal cancer. AUBMC Medicine Grand Round, April 2004
169. Localized Prostate Cancer: Current Management with Radiation and Combined Modality Therapy. The 5th Pan Arab Cancer Congress, Kuwait, April 2004
170. Radiotherapy for pediatric spinal cord compression. Joint meeting Pediatric haematology oncology and pediatric surgery societies, Beirut Lebanon, March 2004
171. Determinants of local control in breast conserving therapy: status of partial breast radiation. The King Hussein Breast cancer conference. Amman, Jordan, March 2004
172. New approaches in Brain tumor radiotherapy: technology or biology? The King Faisal Specialist and Research Hospital, Pediatric Neuro-oncology workshop. Riyadh, Saudi Arabia, March 2004
173. Prostate cancer: New approaches in dose escalation and combined modality. The Syrian Association of Oncology, Prostate Cancer symposium. Palmyra, Syria, March 2004
174. New Approaches in Adjuvant radiation therapy for Brain Tumors. Brain Tumor symposium. Beirut, October 2003
175. Current Standards in adjuvant radiation therapy for rectal cancer. Colorectal Cancer Symposium. Sidon, August 2003
176. Determinants of Local control after conserving therapy for early breast cancer. Annual meeting of the Jordanian Society of Clinical Oncology. Damascus, August 2003
177. Stereotactic and conformal radiation therapy for brain tumors. The Lebanese Society of Neurosurgery, Beirut, July, 2003
178. Local recurrence after breast conserving therapy. The Lebanese Society of Medical Oncology, Jezzine, July, 2003
179. Radiation therapy for high grade gliomas. The Syrian Society of medical oncology, Safita, July 2003
180. Breast cancer: case managements. The Syrian American Medical Society, Damascus, June 2003
181. Prostate cancer: case management, Audience interactive session. The Hospital Committee on cancer biannual workshop. April 2003, Faraya, Lebanon
182. Interventional Radiation oncology. Department of Surgery Grand Round. The University of Beirut Medical Center, November 2002, Beirut, Lebanon
183. Clinical use of amifostine in radiotherapy patients. Jordanian Cancer Society, October 2002, Amman Jordan
184. Advances in radiation therapy for brain tumors. The Lebanese Society of Neurosurgery Annual Meeting. Beirut, October 2002

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

185. Radiation and combined modality therapy for anal cancers. The Lebanese Society of Surgery CME meeting, October 2002, Beirut, Lebanon
186. Radiation Therapy for Breast Cancer with Positive Margins. The Hospital Committee on cancer biannual workshop. September 2002, Faraya, Lebanon
187. Symposium on the Treatment of Hodgkin's disease. Summary and concluding remarks. The Lebanese Society of Medical oncology continued medical education program. April 2002, Beirut Lebanon.
188. Update on the use of radiation therapy in pancreatic cancer. The Hospital Committee on cancer biannual workshop. April 2002, Faraya, Lebanon
189. Radiation therapy for in-stent restenosis. Department of Medicine Grand Round. The University of Beirut Medical Center, April 2002, Beirut, Lebanon
190. Recent Advances in Non-surgical Therapy of Laryngeal Cancer. The Lebanese Society of HN surgery annual meeting, January 2001, Beirut Lebanon.
191. Radiation Therapy for mesothelioma. The Lebanese Society of Medical oncology continued medical education program. February 2001, Beirut Lebanon
192. Radiobiology and physics of intravascular coronary brachytherapy. The Lebanese society of cardiology, July 2001, Beirut Lebanon.
193. Preoperative vs. postoperative radiation therapy for rectal cancer. The Hospital Committee on cancer biannual workshop. September 2001, Faraya, Lebanon.
194. New trends in chemoradiation for locoregionally advanced non small cell lung cancer. The Syrian Order of Physicians CME program. September 2001, Damascus, Syria
195. Clinical Use of Ethyol (Amifostine) in Radiotherapy patients. The Lebanese Society of Medical oncology continued medical education program. November 2001, Beirut Lebanon.
196. Current therapy of Nasopharyngeal Cancer. Department of Oncology, King Faisal Hospital and Research Center, Feb. 2000, Saudi Arabia
197. Combined Hormonal Ablation and Radiation Therapy for Prostate Cancer. The Lebanese society of Urology, April 2000, Beirut Lebanon.
198. Stereotactic Radiosurgery and Stereotactic Radiotherapy Dept. of Neurosurgery, American University of Beirut Medical Center, March 1999
199. Definitive and Adjunctive Therapies for Nasopharyngeal Cancer. Department of Radiation Oncology, St. Luc University Hospital, Universite Catholique de Louvain, June 1999, Brussels, Belgium.
200. Introduction to Radiation Biology for Brain Tumors. Dept. of Neurosurgery, American university of Beirut Medical Center, March 1998
201. Radiotherapy for Brain Tumors. Dept. of Neurosurgery, American university of Beirut Medical Center, March 1998. Advances in Radiation Therapy for gynecological Tumors. Grand Rounds; Dept. of Gynecology, American university of Beirut Medical Center, Dec. 1998
202. Meta-analysis of chemotherapy for head and neck cancer. Investigators meeting, Paris, January, 1997
203. Genetics, Radiosensitivity, and Late Effects of Radiotherapy. International Congress of Radiation Oncology, Beijing, China, June 1997
204. Overview of Modern Radiotherapy. Grand Rounds, Dept. of Surgery, American university of Beirut Medical Center, November 1997
205. In vitro predictors of late normal tissue effects after radiotherapy. 13th annual meeting on Clinical and Experimental Research in Radiation Oncology (CERRO), Les Menuires, France, January 1996
206. Nasopharyngeal cancer: treatment and results of combined therapy. Radiotherapy residents' teaching conference, The University of Texas, M. D. Anderson Cancer Center, Houston TX, January 1996
207. Experimental studies on the radiation response of normal tissues: Predictive assays for late effects. Invited speaker, Gilbert Fletcher Society Annual meeting, Williamsburg, Virginia, April 1996
208. Predictive Assays for Radiation Induced Normal Tissue Damage. Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, April 1996
209. Integration of Chemotherapy and Radiotherapy for Nasopharyngeal cancer. Radiotherapy residents' teaching conference, The University of Texas, M. D. Anderson Cancer Center, Houston TX, December 1996.
210. Treatment of nasopharyngeal carcinoma with radiotherapy. Head and Neck surgery core curriculum course, The University of Texas, M. D. Anderson Cancer Center, Houston TX, January/1995
211. Nasopharyngeal cancer: treatment and results. Radiotherapy residents' teaching conference, The University of Texas, M. D. Anderson Cancer Center, Houston TX, April 1995

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

212. Treatment of nasopharyngeal cancer. Head and Neck surgery core curriculum course, The University of Texas, M. D. Anderson Cancer Center, Houston TX, October 1995
213. Factors affecting normal tissue reactions: Intrinsic cell radiosensitivity. Symposium, Radiation Research Society, Annual Meeting, Nashville, Tennessee, May 1994
214. Hyperfractionation of radiation therapy for head and neck cancers: Rationale, techniques, and results. Beaumont Baptist Hospital, Beaumont, Texas, July 1994
215. Intrinsic normal cell radiosensitivity as a determinant of normal tissue tolerance to radiotherapy. Panel I; American Society for Therapeutic Radiology and Oncology (ASTRO), San Francisco, October 1994.
216. Results of application of treatment modality in radiotherapy. Radiation Therapy and Technology program, Houston, Texas, 12/1994
217. In vitro normal cell radiosensitivity: Potential applications in clinical radiotherapy. University of Tours, University Hospital Bretonneau, Tours, France, February 1993
218. In vitro normal cell radiosensitivity: a potential predictor of normal tissue reactions in patients undergoing radiotherapy. The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, February 1993
219. In vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Workshop 12. Can mechanisms of radiation damage and repair in normal tissues be studied in vitro. Radiation Research Society, Annual Meeting, Dallas, March 1993
220. Prospective comparison between in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. The University of Texas, M. D. Anderson Cancer Center Workshop on future directions in predictive assays. Roundtop, Texas, March 1993
221. In vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Harvard Medical School, Massachusetts's General Hospital, Boston, MA, October 1992
222. In vitro normal cell radiosensitivity: a potential predictor of normal tissue reactions in patients undergoing radiotherapy. University of Ottawa, Ottawa General Hospital, Ontario, Canada, October 1992
223. Fibroblast and lymphocyte radiosensitivity measured in vitro: Individual variation and comparison. The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, June 1991

D. Service

Professional services

President

Lebanese Society of Radiation Oncology
1999-2001
2011-2013

Member,

American Society for Therapeutic Radiology and Oncology (ASTRO)
American Society for Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)
Radiation Research Society (RRS)
European Society for Therapeutic Radiology and Oncology (ESTRO)
Lebanese Cancer Society
Lebanese Society of Radiation Oncology

Associate Editor,

Int. Journal of Radiation Oncology, Biology, and Physics, USA
3/1998 – 2012
European Journal of Surgical Oncology
2013-present
The Cancer Letter
5/2002 – 2010

Reviewer,

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

Journal of Clinical Oncology, USA (ad hoc)
British Journal of Cancer, UK (ad hoc)
Int. Journal of Radiation Biology, UK (ad hoc)
Radiotherapy and Oncology, Denmark (ad hoc)
Int. J. Radiat. Onc. Biol. Phys., USA

Moderator/Chairman

1. Radiological Society of North America (RSNA), 1992; Chair, Radiation Oncology section.
2. The Gilbert Fletcher Society annual meeting; 1997; Chair, Scientific Program
3. Middle East Medical Assembly; 1998; Session Chairman
4. Middle East Medical Assembly; 1999; Scientific Program Committee
5. Lebanese National Meeting on Breast Cancer; 1999; Session Chairman
6. European Soc. of Ther. Radiology and Oncology (ESTRO) 2000; Scientific Program Committee
7. Middle East Cancer Congress; 2001; Scientific Program Committee
8. Lebanese Society of Medical Oncology; 2001; Session Chairman
9. Middle East Medical Assembly, 2002; Chair, Oncology scientific program
10. Lebanese Society of Medical Oncology; 2002; Scientific Program Committee
11. Middle East Cancer Congress; 2003; Scientific Program Committee
12. The Second International Conference on Translational Research in Radiation Oncology, Lugano, Switzerland, 2003; Chair, Session clinical I
13. The American University of Beirut Cancer Program, Vth Educational Symposium, Sept 2003; Moderator, Session on Management of Bone Metastases
14. The Lebanese Society of Radiology, Annual meeting, Beirut, July 2004; Moderator, session on cancer prevention
15. The Lebanese Society of Medical Oncology; Vth annual meeting, Beirut Nov 2004; Moderator, session on prostate cancer management
16. Middle East Medical Assembly, 2006; Coordinator, Joint Oncology program with LSMO-6
17. Middle East Breast Cancer Conference, 2006; Moderator, Session on Adjuvant Radiation
18. Middle East Medical Assembly 2007; Chair; Oncology Scientific Program
19. Middle East Medical Assembly 2009; Chair; Oncology Scientific Program
20. Chairman and Organizer: Women's Cancer conference, Beirut 2011 (Joint conference with the University of Texas MD Anderson cancer Center and King Hussein Cancer center).
21. 7ème Congrès d'Oncologie Francophone & Middle East Forum of Hematologic Malignancies & 4th Lebanese Gynecologic Oncologic Group Annual Meeting; 2016; Member, Scientific Committee.
22. Presidential Symposium Cancer in the Molecular Era: Promise and Prospects; 2016; Moderator, DEBATE on Current and Future Management of Lung Cancer.

American Board Examination

American Board of Radiology; Radiation Oncology
Question item writer for the written examination (1996-1997)

University Services

Chairman

Department of Radiation Oncology; American University of Beirut Medical Center
1997-present

Founding Director

The Naef K. Bassile Cancer Institute; American University of Beirut Medical Center
2007-2012

Chair, Hospital Tumor Board; American University of Beirut Medical Center
1997-2012

Fady B. Geara, M.D., Ph.D. Curriculum Vitae, 1/16/19

Committee Member

Academic Committee

Medical Board

Radiation Safety Committee (Chair)

Hospital Committee on Cancer (Chair)